חוב לטווח קצר להון עצמי Canndoc (INCR)

The debt-to-equity chart for InterCure Ltd. (INCR) demonstrates a ratio of 0.23. InterCure Ltd. (INCR) generates revenue from the sale of cannabis-based pharmaceuticals, leveraging partnerships and pharmacies in the UK, Germany, and Israel. Demand for medicine remains stable, although the business depends on export limits and legislation. Meanwhile, automated greenhouses and processing facilities are operating at maximum productivity.

This indicator compares the volume of confirmed short-term liabilities to equity, identifying liquidity gap risks as refinancing costs rise. By analyzing the trend of loans with maturities up to one year relative to equity, investors assess the financial stability of InterCure Ltd., whose protection via exclusive licenses and a pharmacy network in Israel allows the company to offset market oversupply through stable operating cash flow.